Background: Perinuclear Antineutrophil Cytoplasmic Autoantibodies (pANCA) have been found in patients with rheumatiod arthritis. Cathepsin G was the major target antigen.The present study was to investigate the unknown target antigen of ANCA (Cathapsin G ) in patients with rheumatiod arthritis Objective: This study is to investigate the prevalence of anti-Cathapsin G and rheumatoid factor in Iraqi patients with rheumatiod arthritis.
Patienties&Methods: From1st January until 30 June of 2011 fourty five rheumatiod arthritis patients referred to the immunological department in the teaching laboratory of medical city and twenty five apparently healthy individual used as a control group were investeged to

 Rheumatoid arthritis (RA) was a chronic inflammatory autoimmune disease for long-term that primarily affects small joints and leads to chronic inflammation in synovial. The aimed of the study to identify the relationships among some serological markers (antibodies to citrullinated protein/peptide antigens (ACPAs), anti-mutated citrullinated vimentin (anti-MCV), anti-carbamylated protein (Anti-Carp), anti- heterogeneous nuclear ribonucleoproteins (anti-hnRNP) and Glucose-6-phosphate isomerase (GPI)) and early diagnosis of RA. The study involved (60) Patients of newly diagnosis with RA that divided in to two subgroups (30 RF positive and 30 RF negative) groups and 30 subjects as healthy control group. The serological data from serum

Background: Anti-RA33 antibodies and anti-CCP antibodies are highly specific markers for rheumatoid arthritis (RA), but are not detectable in all RA patients.

Anti-RA33 antibodies are directed to the heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2),while anti-CCP antibodies are directed to modified epitope on proteins that undergo conversion of amino acid arginine to citrullin by citrullination.

Objectives: The aim of this study was to show the correlation between anti-RA33 antibodies, anti-CCP antibodies and rheumatoid factor (RF) in terms of sensitivity and specificity for the diagnosis of rheumatoid arthritis in Iraqi patients.

Subjects and methods: This s

Background. Gene polymorphisms affect etanercept’s pharmacokinetics, pharmacodynamics, and side effects. This effect is evidenced by the extensive genetic variation in the drug’s targets. Objectives. This study aims to find the association between different genotypes of the promoter region of the TNF-α gene at -308G/A(rs1800629), -857C/T(rs1799724), -863 C/A(rs1800630), -1031 T/C (rs1799964), -806 C/T (rs4248158) and -376 G/A (rs1800750) and the side effects of ETN that occurred to Iraqi RA patients. Method. The trial included patients with rheumatoid arthritis who had been using ETN for at least six months. The participants were from the Baghdad Teaching Hospital Rheumatology Unit. The PCR was sequenced to determine the polymo

Background: Rheumatoid arthritis (RA) is an autoimmune disease that results in a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally attacks flexible (synovial) joints. Many cases are believed to result from an interaction between genetic factors and environmental exposures. Epstein-Barr virus (EBV) is associated with several autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis and multip

Background: Rheumatoid Arthritis (RA) is heterogenous syndrome. Because the diversity of disease processes and formation of complex lymphoid microstructures that indicate the multiple T cell activation pathways are involved .affected patients have major abnormalities in the T cell pool with clonally expanded CD4  + T cell that lose expression of the CD28null molecule and lack the ability for profiliration. Adenosine deaminase (ADA) is an indicator of the proliferation and differenation of lymphocyte, in particularly the T cell subcells.
Patients and Methods: Total ADA levels were measured in the sera of RA patients and healthy group according to Giusti (1981).
Results: The mean value of ADA was lo

Rheumatoid arthritis (RA) is one of the autoimmune diseases characterized by the synovial inflammation which causes organs and tissues damage especially synovial tissues and joints. The study included 50 serum samples from patients with rheumatoid arthritis (RA) when compared with 50 serum samples from healthy individuals as control with age range 35 – 60 years (41.3 ± 2.4 years vs. 41.0 ± 2.0 years, respectively). ELISA technique was used to assess the Anti-cyclic citrullinated peptide IgG antibody (anti-CCP IgG Ab) level, anti-rheumatoid factor IgG antibody (anti-RF IgG) and anti-Cytomegalovirus (anti-CMV IgG) antibodies frequencies in the studied groups. The present findings demonstrated that all RA patients have 100% seropositive fr

Background: Cytokines produced by inflammatory cells play a pivotal role in synovial inflammation and joint destruction in rheumatoid arthritis.
Patients and Methods: The cytokine serum levels were measured by EASIA (Enzyme amplified sensitivity immunoassay) in sera from 50 RA patients, and 40 healthy donors. Cytokine levels were compared in different RA subpopulations (positive or negative rheumatoid factor (RF), long term or recent onset disease, high or low disease activity). In addition, the possible association with other demographic and clinical parameters (gender, age, etc) was also analyzed.
Results: It was demonstrated that IL-2, IL-6 and IFN-δ levels were elevated in serum samples of RA pati

Background: Rituximab is a chimeric IgG1 kappa immunoglobulin that has been genetically modified to incorporate human constant region sequences together with murine light- and heavy-chain variable region sequences. People use it to treat rheumatoid arthritis and certain malignancies. Objective: The study aimed to assess the potential association between the serum levels of Factor I, CD59, interleukins (IL)-6, and interferon-gamma (IFN)-γ and the response to Rituximab treatment in Iraqi rheumatoid arthritis patients. Methods: A cross-sectional study was conducted at the rheumatology center at Baghdad Teaching Hospital. Ninety adult patients who have been diagnosed with rheumatoid arthritis and are receiving  Rituximab intravenous i

            Rheumatoid arthritis (RA) is a systematic autoimmune disorder with chronic inflammation changes of unknown etiology. Various synovial inflammatory and proliferative alterations may contribute to the cartilaginous tissues and invasive bony tissues, leading to destructive joints and malformed bones. This disease is mostly due to infective microorganisms or genetic susceptibility causing immune system disturbances through triggering both T-cells and B-cells. Furthermore, different immune cells may secret cytokines, which are responsible for some RA pathogenesis activity. From ninety individuals, serum sample was collected; thirty of them were normal and sixty cases were patients with RA attended a privet medical clin